Head to head
Glaukos vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: GKOS · ABT
GKOS
Glaukos
172.18+6.55%
1-year price shape — +105% over the period
Quant Rating B · 93/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| GKOS | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 172.18 | 98.73 |
| Change today | +6.55% | +0.58% |
| 1-year return | +104.8% | -24.1% |
| Market cap | $10.16B | $170.84B |
| 52-week range | 73.16 – 191.62 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -52.65 | 31.95 |
| P/E percentile, own 5-yr range | 31st | 62nd |
| P/B | 14.88 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | -3.28 | 3.72 |
| Net profit (TTM) | $-193.47M | $6.44B |
| Revenue (TTM) | $612.84M | $46.59B |
| Revenue growth (YoY) | +49.5% | +13.0% |
| Gross margin | 60.7% | 56.6% |
| Operating margin | -31.3% | 15.8% |
| Net margin | -30.7% | 11.6% |
| Free cash flow (TTM) | $-28.80M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 104.1% | 81.2% |
| Insider activity (12mo) | 21 buy / 29 sell | 36 buy / 12 sell |
| Short interest (% of float) | 7.1% | 1.1% |
| Analyst consensus | 92% buy / 8% hold (13) | 100% buy (14) |
| Analyst price target | $197 (+15%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | B (93) | E (15) |
| Company | ||
| Employees | 1,094 | 115,000 |
| Founded | 1998 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.